Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06651294

Efficacy of Neorenal Forte for the Complete Elimination of Residual Fragments

Efficacy and Safety of Neorenal Forte as Adjuvant Treatment for the Complete Elimination of Residual Fragments After Flexible Ureterorenoscopy With Laser Lithotripsy for Renal Calculi.

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
120 (estimated)
Sponsor
Neopharm Bulgaria Ltd. · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the efficacy of a specialized formula of phytotherapeutic extracts (Neorenal Forte) aiding the complete elimination of residual fragments after fURS in adults.

Detailed description

The study is being initiated to support the informed decision making by healthcare specialists on the initiation of a specific and safe formula of phytotherapeutic extracts with duration at least three months after endourological procedures, as a routine part of urolithiasis treatment, aiding the complete elimination of residual fragments, which will allow minimizing of the short-term and long-term complications. By evaluating the percentage of complete elimination of residual fragments or fragments \< 2 mm in diameter, we aim to estimat the efficacy and safety of Neorenal Forte.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTNeorenal ForteThis specialized formulation of phytotherapeutic extracts consists of proprietary Betula pendula leaves dry extract, Herniaria glabra, Viburnum opulus, Elymus (Agropiren) repens. The product contains supplementary ingredients: microcrystalline cellulose, povidone, magnesium stearate, colorant film (brilliant blue FCF, iron dioxide).
DIETARY_SUPPLEMENTPlaceboThe placebo product will be identical to the active form and will have the same composition but without the proprietary extract from Betula pendula, Herniaria glabra, Viburnum opulus, Elymus (Agropiren) repens.

Timeline

Start date
2025-04-01
Primary completion
2026-10-30
Completion
2026-11-30
First posted
2024-10-21
Last updated
2025-11-28

Locations

9 sites across 1 country: Bulgaria

Source: ClinicalTrials.gov record NCT06651294. Inclusion in this directory is not an endorsement.